Of 68.ative approach to treating mantle cell lymphoma results in a high complete remission ratemantle cell lymphoma, a subtype of adult non-Hodgkin’s lymphoma , which represents approximately 5 percent of NHL in the United States and Europe. Standard treatment of mantle cell lymphoma with chemotherapy poor results poor results in the promotion of survival, suggesting that new and innovative treatments are being explored. Doctors from Memorial Sloan – Kettering Cancer Center in New York City increased the clinical challenge and presented their findings at the Society of Nuclear Medicine 51st Annual Meeting.
Although mantle cell lymphoma is extremely radiosensitive, was not sufficient treatment of MCL because of their systemic nature. The researchers presumed that by the administration of RIT after after 13-16 weeks with 6 rounds chemotherapy, they could first reduce the tumor burden, then reach the systemic disease.The nation’s first national laboratory, Argonne National Laboratory in Center conducts basic research and applied research in a broad spectrum from events, ranging from high-energy physics for the climatology and biotech. Information please contact 1990, Argonne collaborated with more than 600 companies and many Federal Authorities of and helping help preliminary American scientific leadership and prepare the Country for the future. Argonne run by the University of Chicago of the U.S. Department of Energy Office of Science. For further information, please contact Catherine Foster States – at the Argonne.